| 1 |
[GO] |
2024―Dez―20 |
Pre-exposure prophylaxis of COVID-19 with tixagevimab/cilgavimab (Evusheld) in 63 rituximab-treated patients with ANCA-associated systemic vasculitis: two-year follow-up results |
T. V. Beketova, N. O. Levina, Yu. A. Uskova, I. V. Rozanova, M. V. Dubinskaia, S. A. Evdokimova, et al. (+3) V. V. Babak, M. F. Beketova, A. V. Devyatkin |
| 2 |
[GO] |
2024―Mrz―05 |
Risk factors for severe COVID-19 in patients with rheumatic diseases |
A. N. Kulikov, N. V. Muravyeva, B. S. Belov |
| 3 |
[GO] |
2024―Mrz―05 |
Coronavirus disease 2019 (COVID-19) pandemic and autoimmune rheumatic diseases: Outcomes and prospects |
E. L. Nasonov |
| 4 |
[GO] |
2023―Dez―27 |
Frequency and course of COVID-19 in patients with rheumatic diseases (according to the data of V.A. Nasonova Research Institute of Rheumatology) |
A. N. Kulikov, N. V. Muravyeva, B. S. Belov |
| 5 |
[GO] |
2023―Aug―31 |
Rheumatoid arthritis and COVID-19: Three years later |
B. S. Belov, E. S. Aronova, G. I. Gridneva, E. I. Nasonov |
| 6 |
[GO] |
2023―Mrz―23 |
COVID-19 in a patient with granulomatosis with polyangiitis: Management tactics |
E. F. Iskhakova, E. V. Sukhorukova, M. Yu. Badeeva, E. V. Dyakova, S. A. Lapshina, T. V. Beketova, D. I. Abdulganieva |
| 7 |
[GO] |
2023―Mrz―23 |
Multifocal osteonecrosis as a consequence of a new coronavirus infection |
A. A. Klimenko, N. A. Demidova, D. Yu. Andryashkina, N. M. Babadayeva, A. A. Kondrashov, Yu. M. Saakyan |
| 8 |
[GO] |
2023―Mrz―23 |
Results of a 12-week open-label, non-interventional study of the efficacy and safety of olokizumab therapy in patients with rheumatoid arthritis after switching from anti-B-cell therapy during the SARS-CoV-2 pandemic |
A. A. Akimova, N. E. Banshchikova, A. E. Sizikov, A. A. Mullagaliev, E. A. Letyagina, N. A. Ilina, et al. (+6) Yu. D. Kurochkina, Yu. B. Ubshaeva, V. O. Omelchenko, O. A. Chumasova, N. S. Shkaruba, M. A. Korolev |
| 9 |
[GO] |
2022―Dez―26 |
Avascular necrosis of the epiphyses of bones in patients who have had SARS-CoV-2 infection: Clinical observations and a narrative review of literature data |
V. E. Bialik, A. E. Karateev, E. I. Bialik, M. A. Makarov, S. A. Makarov, A. A. Roskidailo, et al. (+3) V. A. Nesterenko, A. M. Lila, M. A. Malygina |
| 10 |
[GO] |
2022―Sep―08 |
COVID-19 in women with ankylosing spondylitis during pregnancy and within one year after childbirth |
O. A. Krichevskaya, T. V. Dubinina, E. V. Ilinykh, A. B. Demina, I. A. Andrianova |
| 11 |
[GO] |
2022―Jul―11 |
Features of the course and outcomes of COVID-19 in patients with axial spondyloarthritis |
Sh. F. Erdes |
| 12 |
[GO] |
2022―Jul―11 |
Autoantibodies and SARS-CoV-2 infection: A case report |
T. I. Kalenchic, S. L. Kabak, I. V. Korenevskaya |
| 13 |
[GO] |
2022―Mai―16 |
Interleukin 18 in Immune-mediated rheumatic diseases and COVID-19 |
E. L. Nasonov, A. S. Avdeeva |
| 14 |
[GO] |
2022―Mai―16 |
On the issue of post COVID-19 condition in patients with rheumatic diseases |
M. F. Beketova, V. V. Babak, M. D. Suprun, T. V. Beketova, O. A. Georginova |
| 15 |
[GO] |
2022―Mai―16 |
The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients |
A. E. Karateev, E. Yu. Polishchuk, A. S. Potapova, E. V. Matyanova, A. S. Semashko, А. O. Bobkova, et al. (+5) E. S. Filatova, V. N. Amirjanova, S. I. Glukhova, E. G. Zotkin, A. M. Lila |
| 16 |
[GO] |
2022―Mai―16 |
Effect of COVID-19 coronavirus infection on the course of rheumatoid arthritis |
V. N. Sorotskaya, A. O. Plakhova, B. B. Halmuradova, D. S. Vaisman, R. M. Balabanova |
| 17 |
[GO] |
2022―Mrz―02 |
Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues |
B. S. Belov, A. M. Lila, E. L. Nasonov |
| 18 |
[GO] |
2021―Dez―27 |
Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review |
E. L. Nasonov, B. S. Belov, A. M. Lila, E. S. Aronova, G. I. Gridneva, A. V. Kudryavtseva, et al. (+5) E. V. Sokol, A. V. Torgashina, I. B. Vinogradova, D. I. Abdulganieva, A. Yu. Zimenko |
| 19 |
[GO] |
2021―Dez―27 |
Anxiety, depression and stress tension screening in patients with rheumatic and musculoskeletal diseases at the onset of the 2019 coronavirus disease (COVID-19) pandemic |
A. B. Borisova, T. A. Lisitsyna, D. Yu. Veltishchev, E. L. Nasonov |
| 20 |
[GO] |
2021―Sep―06 |
B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19) |
E. L. Nasonov, A. S. Avdeeva |
| 21 |
[GO] |
2021―Jul―15 |
Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia |
E. L. Nasonov, A. M. Lila, V. I. Mazurov, B. S. Belov, A. E. Karateev, T. V. Dubinina, et al. (+5) O. A. Nikitinskaya, A. A. Baranov, D. I. Abdulganieva, S. V. Moiseev, A. I. Zagrebneva |
| 22 |
[GO] |
2021―Mai―13 |
Problems of early diagnosis of systemic lupus erythematosus during the COVID-19 pandemic |
E. L. Nasonov, T. V. Popkova, T. A. Panafidina |
| 23 |
[GO] |
2021―Mrz―03 |
Coronavirus disease 2019 (COVID-19) and autoimmunity |
E. L. Nasonov |
| 24 |
[GO] |
2021―Mrz―03 |
COVID-19 and rheumatology: A year later |
B. S. Belov, A. M. Lila |
| 25 |
[GO] |
2021―Mrz―03 |
The course and outcomes of COVID-19 in patients with ANCA-associated systemic vasculitis, receiving biological therapy (Rituximab, Mepolizumab): The results of the first 8 months of the pandemic |
T. V. Beketova, V. V. Babak, M. D. Suprun |
| 26 |
[GO] |
2021―Jan―15 |
Remote monitoring of patients with axial spondyloarthritis during the COVID-19 pandemic: results and prospects of using the information technology “Aspine” |
D. G. Rumiantceva, A. M. Lila, Sh. Erdes |
| 27 |
[GO] |
2020―Nov―10 |
Coronavirus Desease 2019 (COVID-19) in Children: Lessons from Pediatric Rheumatology |
M. I. Kaleda, I. P. Nikishina, E. S. Fedorov, E. L. Nasonov |
| 28 |
[GO] |
2020―Sep―09 |
Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity |
E. L. Nasonov, T. V. Beketova, T. M. Reshetnyak, A. M. Lila, L. P. Ananieva, T. A. Lisitsyna, S. K. Soloviev |
| 29 |
[GO] |
2020―Sep―09 |
Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab) |
T. V. Beketova, L. M. Blank, A. M. Lila |
| 30 |
[GO] |
2020―Jun―24 |
DO NSAIDS CAUSE SPECIFIC COMPLICATIONS IN COVID-19 CORONAVIRUS INFECTION? |
A. E. Karateev, E. L. Nasonov, A. M. Lila |
| 31 |
[GO] |
2020―Jun―24 |
IMMUNOPATHOLOGY AND IMMUNOPHARMACOTHERAPY OF CORONAVIRUS DISEASE 2019 (COVID-19): FOCUS ON INTERLEUKIN 6 |
E. L. Nasonov |
| 32 |
[GO] |
2020―Apr―27 |
CORONAVIRUS DISEASE 2019 (COVID-19): A RHEUMATOLOGIST’S THOUGHTS |
E. L. Nasonov |
